CN113288962B - Traditional Chinese medicine preparation for treating non-lactation mastitis and preparation method thereof - Google Patents
Traditional Chinese medicine preparation for treating non-lactation mastitis and preparation method thereof Download PDFInfo
- Publication number
- CN113288962B CN113288962B CN202110641774.2A CN202110641774A CN113288962B CN 113288962 B CN113288962 B CN 113288962B CN 202110641774 A CN202110641774 A CN 202110641774A CN 113288962 B CN113288962 B CN 113288962B
- Authority
- CN
- China
- Prior art keywords
- fructus
- preparation
- mastitis
- treating non
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000004396 mastitis Diseases 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 230000006651 lactation Effects 0.000 title claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 18
- 241000255789 Bombyx mori Species 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 13
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 13
- 241000245665 Taraxacum Species 0.000 claims abstract description 12
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000222684 Grifola Species 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000012153 distilled water Substances 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 238000007873 sieving Methods 0.000 claims abstract description 3
- 238000001256 steam distillation Methods 0.000 claims abstract description 3
- 239000000341 volatile oil Substances 0.000 claims abstract description 3
- 230000002829 reductive effect Effects 0.000 claims description 11
- 244000111489 Gardenia augusta Species 0.000 claims description 7
- 244000171085 Polyporus umbellatus Species 0.000 claims description 7
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 241000202726 Bupleurum Species 0.000 claims description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 4
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 4
- 240000006023 Trichosanthes kirilowii Species 0.000 claims description 4
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 241000207929 Scutellaria Species 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 239000000284 extract Substances 0.000 abstract description 8
- 241000255791 Bombyx Species 0.000 abstract description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract description 2
- 241000222640 Polyporus Species 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 102000004889 Interleukin-6 Human genes 0.000 description 15
- 108090001005 Interleukin-6 Proteins 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 12
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 12
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 12
- 230000008961 swelling Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102100038595 Estrogen receptor Human genes 0.000 description 7
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 7
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 7
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 7
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 6
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 102100035721 Syndecan-1 Human genes 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000780272 Mammilla Species 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 240000004534 Scutellaria baicalensis Species 0.000 description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 3
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 3
- 244000078912 Trichosanthes cucumerina Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- 240000007311 Commiphora myrrha Species 0.000 description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 description 2
- 208000002628 Granulomatous mastitis Diseases 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 206010066170 Plasma cell mastitis Diseases 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000010758 granulomatous inflammation Diseases 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Insects & Arthropods (AREA)
- Gynecology & Obstetrics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine preparation for treating non-lactation mastitis, which is prepared from the following main raw materials in parts by weight: radix bupleuri, radix scutellariae, rhizoma cyperi, dandelion, fructus forsythiae, fructus trichosanthis, fructus gardeniae, stiff silkworm, grifola and poria cocos. The invention also discloses a preparation method for treating non-lactation mastitis, which comprises the following steps: (1) pulverizing Bombyx Batryticatus, Poria and Polyporus into powder, extracting with ethanol twice, filtering, and collecting the first extractive solution; (2) slicing fructus forsythiae, extracting volatile oil by steam distillation, and collecting second extractive solution; (3) mixing bupleuri radix, Scutellariae radix, rhizoma Cyperi, herba Taraxaci, fructus Trichosanthis and fructus Gardeniae, adding distilled water, decocting, and sieving to obtain a third extractive solution; the traditional Chinese medicine decoction can effectively extract the effective components of the medicine, is more convenient to take in a brewing mode, and has better clinical curative effect on treating non-lactation mastitis compared with the traditional liver-soothing and stasis-removing decoction.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine preparation with effects of clearing heat and removing toxicity, soothing liver and dissipating stagnation and used for treating non-lactation mastitis and a preparation method thereof.
Background
Non-lactation mastitis is a general term for a group of non-lactation mastitis, and gradually enters the public sight line with the annual rise of the incidence rate. Non-lactation mastitis has the characteristics of long course of disease, easy repetition and great influence on the appearance of breasts, and is called cancer in inflammation. According to the pathological characteristics, the common types are plasma cell mastitis and granulomatous mastitis, wherein the former is pathologically characterized by inflammatory cell infiltration around a large duct, and the latter is pathologically characterized by terminal duct lobular granulomatous inflammation. However, the two are often difficult to distinguish clinically, and even mixed, the patient has both large duct inflammation and granulomatous change of peripheral mammary lobules, especially when the mass is large, the pathology can have inflammatory cell infiltration around the large duct and granulomatous inflammation of terminal duct lobules at the same time. At present, the treatment of non-lactation mastitis is mainly surgical treatment and conservative treatment, although a certain curative effect can be obtained by surgical excision, a certain surgical time is needed, the breast is seriously damaged, and most of patients still tend to be treated conservatively. The medicine conservation treatment mainly comprises western medicine and traditional Chinese medicine, the western medicine mainly aims at the anti-inflammation and the immune regulation aiming at the etiology, and the glucocorticoid is used as a common medicine due to the strong anti-inflammation and immune regulation effects. The traditional Chinese medicine treatment is proved to have the effects of resisting inflammation and regulating immunity under the condition of definite clinical curative effect.
Non-lactation mastitis is called acne type acute mastitis in traditional Chinese medicine, and the pathogenesis of the mastitis is generally considered to be the inter-operative mechanism of liver channel intrinsic heat, qi and blood stasis and phlegm and blood stasis. The professor of the life of the people conceivably thinks that the occurrence and the development of non-lactation mastitis are closely related to the liver and the stomach. The disease has a long course, namely the process of transforming yin into yang, wherein stagnation of liver qi and stagnation of stomach qi are in the initial stage, then stagnation of liver qi transforms into fire, phlegm stagnation transforms into heat, and heat is transmitted to the flesh to cause rottenness. Clinical observation proves that non-lactation mastitis patients often show a group of symptoms of stagnated heat of liver and stomach and intermingled phlegm and blood stasis: irritability, premenstrual distention, chest distress, dry mouth, polydipsia, bitter taste in mouth, halitosis, malnutrition of mouth and tongue, constipation, yellow urine, acne, reddened tongue, thin yellow or yellow greasy coating, wiry and thready smooth pulse, etc. The empirical formula of the liver soothing and stagnation eliminating decoction is clinically used for many years, and has a remarkable curative effect. In the formula, radix bupleuri and rhizoma cyperi have the effects of soothing liver-qi stagnation, snakegourd fruit has the effects of promoting blood circulation and removing blood stasis, dandelion, scutellaria baicalensis, gardenia jasminoides and fructus forsythiae have the effects of clearing liver-fire and stomach-fire, and hoelen and stiff silkworm are added to the formula for tonifying spleen, reducing phlegm, inducing diuresis, relieving swelling and resolving masses. The whole formula soothes liver and promotes qi circulation, clears stomach and purges heat, and reduces swelling and stagnation.
Disclosure of Invention
The purpose of the invention is as follows: aiming at the problems or the defects in the prior art, the invention provides a traditional Chinese medicine preparation for treating non-lactation mastitis and a preparation method thereof.
In order to achieve the purpose, the embodiment of the invention provides a traditional Chinese medicine preparation for treating non-lactation mastitis, which is characterized by being prepared from the following main raw materials in parts by weight: 10g of radix bupleuri, 10g of scutellaria baicalensis, 10g of rhizoma cyperi, 30g of dandelion, 10g of fructus forsythiae, 10g of trichosanthes kirilowii Maxim, 10g of gardenia, 10g of stiff silkworm, 10g of polyporus umbellatus and 10g of poria cocos.
The embodiment of the invention also provides a preparation method for treating non-lactation mastitis, which is characterized by comprising the following steps:
(1) the preparation method comprises the following steps of crushing batryticated silkworm, tuckahoe and polyporus umbellatus according to a formula ratio to prepare stiff silkworm powder, tuckahoe powder and polyporus umbellatus powder, adding 65-90% ethanol to extract for two times, each time lasts for 2-3 hours, filtering, and collecting a first extracting solution;
(2) slicing fructus forsythiae, extracting volatile oil by steam distillation, and collecting second extractive solution;
(3) mixing the bupleurum, the scutellaria, the rhizoma cyperi, the dandelion, the trichosanthes kirilowii maxim and the gardenia according to the formula amount, adding sufficient distilled water, decocting for 30-60 minutes, and sieving by a 80-mesh sieve to obtain a third extracting solution;
(4) adding the first extracting solution obtained in the step (1) and the second extracting solution obtained in the step (2) into the third extracting solution obtained in the step (3), and performing reduced pressure drying by adopting a cabinet type reduced pressure dryer to obtain dried powder;
(5) further crushing the medicinal powder obtained in the step (4) into fine powder with the granularity of more than 100 meshes by using a traditional Chinese medicine ultrafine pulverizer;
(6) at an ozone concentration of 50g/m3Air flow speed of 40m/s and air source oxygen purity>And (4) carrying out ozone sterilization on the fine powder obtained in the step (5) at the sterilization temperature of less than 40 ℃ at 85%, preserving the medicinal components under the maximum condition, and preparing the Chinese medicinal preparation.
Preferably, the fine powder obtained in step (5) requires: 100 percent of the mixture is sieved by a 100-mesh sieve, and 95 percent of the mixture is sieved by a 120-mesh sieve.
Preferably, in the step (1), the step (2) and the step (3), the weight of the radix bupleuri, the radix scutellariae, the rhizoma cyperi, the fructus forsythiae, the fructus trichosanthis, the fructus gardeniae, the stiff silkworm, the polyporus umbellatus and the poria cocos is the same, and the weight of the dandelion is 3 times of that of any other materials.
The technical scheme of the invention has the following beneficial effects:
(1) the traditional Chinese medicine preparation for treating non-lactation mastitis and the preparation method thereof can effectively extract effective components of the medicine, the medicine is convenient to brew and take, and the clinical curative effect of the traditional Chinese medicine preparation for treating non-lactation mastitis is better than that of the traditional liver-soothing and stasis-removing decoction.
(2) Compared with the traditional prescription of liver-soothing and stasis-removing decoction in the hospital, the traditional Chinese medicine preparation for treating non-lactation mastitis disclosed by the invention has the advantages that the medicinal flavor is reduced, the cost is reduced, the achieved effect is better than that of the traditional liver-soothing and stasis-removing decoction, and the market value is higher.
(3) The preparation method of the traditional Chinese medicine preparation for treating non-lactation mastitis classifies different medicinal materials, extracts effective liquid in different modes, and prepares dry medicinal powder by a cabinet type reduced pressure dryer reduced pressure drying method, so that the loss of effective components of different medicinal materials is reduced to a greater extent.
(4) The bupleurum root adopted in the invention has the functions of soothing liver-qi stagnation, promoting blood circulation to arrest pain, reducing swelling and promoting granulation, and the extract of the bupleurum root can relieve pain, diminish inflammation, increase white blood cells and promote granulation growth. The adopted scutellaria baicalensis has the effects of clearing heat, purging fire and detoxifying. The effective components have antibacterial, antiinflammatory, antipyretic, and antiallergic effects. The rhizoma Cyperi has effects of dispersing stagnated liver qi for relieving qi stagnation, and its effective component has analgesic effect, and is suitable for breast pain caused by stagnation of qi due to stagnation of liver-qi. The adopted fructus forsythiae has the effects of clearing away heat and toxic materials, relieving swelling and dissipating stagnation, and modern pharmacological research shows that the fructus forsythiae has the effects of bacteriostasis, anti-inflammation, immunoregulation, antioxidation and the like. The adopted snakegourd fruit has the effects of clearing heat and removing phlegm, and relieving chest stuffiness and dissipating stagnation, and the effective components of the snakegourd fruit have the antibacterial effect. The adopted gardenia: has the functions of clearing heat and promoting diuresis, cooling blood and removing toxicity, and relieving swelling and pain. The effective components of the water extract have antipyretic, antibacterial, antiinflammatory, tranquilizing, analgesic, and immunity regulating effects. The Bombyx Batryticatus has effects of eliminating phlegm, resolving hard mass, dispelling pathogenic wind and relieving pain. The effective components of the alcohol-water leaching solution have tranquilizing, anti-inflammatory and antibacterial effects. The adopted polyporus umbellatus has the effects of promoting diuresis and excreting dampness, and the water extract and the alcohol extract of the polyporus umbellatus have the effects of regulating immunity and inhibiting bacteria respectively. The adopted Poria has effects of promoting diuresis and eliminating dampness, and its alcohol extract has effects of tranquilizing mind, promoting urination, and regulating immunity. The herba Taraxaci has effects of clearing heat and detoxicating, detumescence and resolving hard mass, promoting diuresis and treating stranguria, and its effective components have antibacterial and immunity enhancing effects.
Drawings
FIG. 1 is a graph showing that XSGSJT has a significant therapeutic effect on local inflammation in rats in the embodiment of the present invention.
Wherein, fig. 1A is a comparison graph of papilla conditions of a control group, a model group, an XSGSJT high dose group and an XSGSJT low dose group after modeling rats; FIG. 1B is a graph of HE staining results in the NPM model for the control, model, XSGSJT high dose and XSGSJT low dose groups.
FIG. 2 is a graph showing that XSGSJT inhibits the expression of CD138, IL-6, EGFR, ESR1 and NOS3 in rat mammary tissue in an example of the present invention. Wherein, FIG. 2A is the expression pattern of rat mammary tissue CD138 of the control group, the model group, the XSGSJT high dose group and the XSGSJT low dose group. FIGS. 2B-2E are graphs showing the expression of IL-6, EGFR, ESR1, and NOS3 in mammary tissue of rats detected in the control group, model group, XSGSJT high dose group, and XSGSJT low dose group. FIG. 2F is a graph showing the expression of IL-6 and EGFR in the control, model, XSGSJT high dose and XSGSJT low dose groups.
FIG. 3 is a graph of the IL-6/STAT3 signaling pathway for XSGSJT reversal of mastitis model-induced activation in an example of the present invention. Wherein, FIGS. 3A-3F are expression profiles of IL-6 and EGFR, p-JAK2, p-STAT3, p-JAK2/JAK2, and p-STAT3/STAT3 in the control group, the model group, the XSGSJT high dose group, and the XSGSJT low dose group.
Detailed Description
In order to make the technical problems, technical solutions and advantages to be solved by the present invention clearer, the following detailed description is given with reference to specific embodiments.
In the present examples, the following are definitions of abbreviations: XSGSJT (inventive preparation, XINSHUGANSAOJIE decoction); SGSJT (traditional liver soothing and stasis removing decoction); NPM (non-lactating mastitis).
The medicament formula (10 g of radix bupleuri, radix scutellariae, rhizoma cyperi, fructus forsythiae, trichosanthes kirilowii maxim, gardenia, stiff silkworm, grifola, poria cocos and 30g of dandelion) is prepared from traditional formula liver-soothing and stasis-removing decoction (10 g of radix bupleuri, rhizoma cyperi preparata, myrrh, radix scutellariae, gardenia, honeysuckle, fructus forsythiae, pericarpium citri reticulatae viride and pericarpium citri reticulatae) of the hospital, 15g of fructus trichosanthis, radix salviae miltiorrhizae, grifola, poria cocos and roasted stiff silkworm, 60g of raw oyster and 30g of dandelion and raw malt respectively).
General data: retrospective studies are included in 2017-2020 outpatients and 164 hospitalized non-lactation mastitis patients in Nantong city, wherein 84 new liver soothing and stasis removing soup groups (XSGSJT) and 80 new liver soothing and stasis removing Soup Groups (SGSJT) have no statistical difference in general data (age, onset time and pathological type) of two groups, and the two groups have comparability.
In the table, PCM is plasma cell mastitis, GLM is granulomatous mastitis, and is two typical types of non-lactation mastitis, T is a T test value, chi 2 is a chi square test value, P is a test result, and P is more than 0.05, and no difference exists.
As can be seen from the above table, 84 patients are selected to be treated by the new liver-soothing and stagnation-eliminating decoction, and 80 patients are treated by the liver-soothing and stagnation-eliminating decoction, wherein the average time of the attack is close to that of the new liver-soothing and stagnation-eliminating decoction, the number of patients with the pathology of PCM is 53, and the number of patients with the pathology of GLM is 31 in the new liver-soothing and stagnation-eliminating decoction group; in the liver soothing and stagnation removing decoction group, the number of patients with the pathological condition of PCM is 50, and the number of patients with the pathological condition of GLM is 30.
Example 1
SGSJT group patients take liver soothing and stasis removing soup (10 g each of radix bupleuri, rhizoma cyperi preparata, myrrh, radix scutellariae, fructus gardeniae, honeysuckle, fructus forsythiae, pericarpium citri reticulatae viride and pericarpium citri reticulatae, 15g each of fructus trichosanthis, radix salviae miltiorrhizae, grifola, poria cocos and roasted stiff silkworm, 60g of raw oyster, 30g each of dandelion and raw malt, the traditional Chinese medicines in the same batch provided by Nantong Sanyue medical industry) 1 dose a day, and the decoction is decocted to 300ml and half taken in the morning and evening until the patients are healed.
The XSGSJT group takes the preparation of the new liver soothing and stasis removing decoction (10 g of radix bupleuri, 10g of radix scutellariae, 10g of rhizoma cyperi, 30g of dandelion, 10g of fructus forsythiae, 10g of fructus trichosanthis, 10g of fructus gardeniae, 10g of stiff silkworm, 10g of grifola and 10g of poria cocos) of the invention 1 dose per day, the dosage is adjusted to 300ml by warm boiled water, and half of the decoction is taken in the morning and at night until the patients are fully cured.
Example 2 statistical method
Observation indexes are as follows: integration of clinical symptom signs: the size of the tumor: measuring the longest diameter value of the tumor under ultrasound by the same sonographer, calculating the sum of the major diameters when a plurality of tumors are measured, wherein the major diameter is less than or equal to 3cm and is 1 minute, the major diameter is more than 3cm and is less than or equal to 6cm and is 2 minutes, the major diameter is more than 6cm and is less than or equal to 9cm and is 3 minutes, and the major diameter is more than 9cm and is 4 minutes; skin color: selecting one of normal skin color, reddish, red and bright red by a senior specialist, obtaining the consent of a patient, then taking a picture, judging the skin color by taking the picture as a standard, and respectively recording 1-4 points; skin temperature: measuring the temperature of the red and swollen part and the surrounding normal part by using a forehead temperature gun of the same type, wherein the temperature is equal to 1 minute, the temperature is 2 minutes when the temperature is higher than or equal to 1 ℃, the temperature is 3 minutes when the temperature is higher than 1 ℃ and is less than or equal to 2 ℃, and the temperature is 4 minutes when the temperature is higher than 2 ℃; pain: pain-free was scored 1, occasional pain and slight pain were scored 2, occasional pain but more severe or mild pain persisted as 3, and persistent more severe pain was scored 4. Data were counted once each at the time of group entry and after treatment completion.
(II) White Blood Cells (WBC), C-reactive protein (CRP): the detection is carried out once at the time of group entry and one month after treatment. Venous blood was drawn on an empty stomach early in the morning after admission to the hospital for all patients.
(III) healing time: the time from the start of treatment to healing under ultrasound.
(IV) recurrence rate: recurrence rate after the half-year of recovery.
Statistical analysis of the data was performed using SPSS 20.0. For data conforming to normal distribution, metering data is expressed in (x +/-s), independent sample t test is adopted among groups, paired sample t test is adopted in groups, and counting data is subjected to 2 test; non-normal distribution data are tested by non-parametric test, and the measurement data are expressed by M (P25-P75). Significant differences were indicated by P < 0.05.
As a result: compared with the SGSJT group, the XSGSJT group can more effectively and rapidly improve the local red swelling and hot pain symptoms of patients (table one), improve the laboratory indexes related to inflammation (table two), shorten the cure time and lower the recurrence rate (table three).
TABLE-local red swelling and hot pain table for patients treated by XSGSJT group and SGSJT group
The clinical manifestations of non-lactation mastitis have red swelling and hot pain, the first table is an evaluation table of indexes such as mass size, skin color temperature, pain and the like of an XSGSJT group and an SGSJT group before and after treatment according to a clinical symptom sign integral method, and the XSGSJT group is obvious in tumor reduction and more normal in skin color temperature and pain reduction after treatment by different medicines.
TABLE II XSGSJT group and SGSJT group patients laboratory index table related to inflammation improvement
Venous blood is extracted from early morning after admission of all patients, and the venous blood is detected once each time when the patients are put into groups and after treatment for one month; from the second table, White Blood Cells (WBC) and C-reactive protein (CRP) data are shown, and after treatment, compared with SGSJT patients, the XSGSJT group has lower leukocyte and C-reactive protein values and more obvious inflammation improvement, t is the statistic of t test, P is the judgment on the result, P is less than 0.05, and the difference has statistical significance.
Table of the cure time and recurrence rate of patients in the three XSGSJT and SGSJT groups
As can be seen from table three, the mean healing time of the XSGSJT group is 45.42 +/-22.56 days, while the healing time of the SGSJT group is 60.81 +/-35.79, and the healing time of the XSGSJT group is shorter than that of the SGSJT group; the recurrence rate of the XSGSJT group is lower in recurrence rate, t is the statistic of t test, chi 2 is the statistic of chi 2 test, P is the judgment of the result, P is less than 0.05, and the difference has statistical significance.
Example 3 animal experiments:
in order to more objectively confirm the efficacy of the preparation of the present invention and to perform toxicological experiments, the present invention performed rat experiments.
The experimental method comprises the following steps:
SD rats were selected and a rat mastitis model was established by subcutaneous injection of tissue homogenate inoculum prepared from tissue surgically removed from pathologically confirmed non-lactating mastitis patients, and model rats were given a low XSGSJT dose (0.018mL/g) and a high XSGSJT dose (0.036 mL/g).
The results were as follows:
XSGSJT has obvious therapeutic effect on local red swelling of rats. As shown in FIG. 1A, the papilla of the control group was normal after the rat was modeled, and the papilla of the model group showed red and swollen lesions, and small and hard lumps were formed around the breast. After 3 weeks of modeling, there was significant inflammation of the papilla macroscopically. After XSGSJT treatment, the mammilla of the two mastitis models is improved, the red and swollen mammilla disappears, the mammilla returns to normal milk white color, and the subcutaneous small hard mass around the mammilla disappears. Furthermore, the XSGSJT high dose group had a more significant effect than the XSGSJT low dose group. This part of the results shows that after one week XSGSJT has a significant therapeutic effect on NPM localized redness.
The above results were confirmed by HE staining. It can be observed that in the NPM model, there was lymphocyte infiltration in the leaflets, disappearance of the intrabulbar ducts, and a difference in the degree of lymphocyte infiltration around the interstitial capillaries. Inflammatory granulomatous lesions were distributed along the lobules of the breast, with portions of the lesions merging and the ducts of the lobules diminishing or disappearing (fig. 1B). After low dose XSGSJT treatment, inflammation was reduced, but compared to the control group, inflammation remained and nuclear accumulation occurred. Furthermore, inflammation was significantly reduced in the high dose group and the duct inflammation was alleviated (fig. 1B), suggesting that XSGSJT may lead to a reduction in inflammation in both mastitis models.
XSGSJT inhibits the expression of CD138, IL-6, EGFR, ESR1, and NOS3 in rat mammary tissue. Knowing that plasma cells are from B lymphocytes, the presence of large numbers of B lymphocytes in chronic mastitis next, the present invention uses immunohistochemistry to detect CD138 expression, which is a specific indicator of plasma cells. It was found that the expression of CD138 in mammary tissue of rats in the model group was highly increased and decreased after treatment with low dose XSGSJT, with the expression in the high dose group being lower than in the low dose group (fig. 2A). Previous network-based pharmacological studies by the inventors of the present invention found that IL-6, EGFR, ESR1, NOS3 are key targets of XSGSJT in PCM treatment, and therefore IL-6, EGFR, ESR1, and NOS3 expression in rat mammary tissue was detected and showed increased expression of IL-6, EGFR, ESR1, NOS3 after model establishment (p <0.05, fig. 2B-fig. 2E), with decreased expression with increasing XSGSJT dose, with less decrease in ESR1 and NOS3 expression (fig. 2B-fig. 2E). Thus, the present invention verifies the expression of IL-6 and EGFR in rat mammary tissue by immunohistochemistry alone. As a result, mastitis model promoted IL-6 and EGFR expression, with IL-6 and EGFR inhibition as XSGSJT dose was increased (FIG. 2F).
(III) XSGSJT reverses activation of the IL-6/STAT3 pathway by mastitis model
Subsequently, protein expression associated with the STAT3 pathway was determined. First, IL-6 and EGFR were upregulated in the model group, and downregulated in the low and high dose groups (p <0.001, FIGS. 3A-3B). Similarly, modeling induced expression of p-JAK2, p-STAT3, p-JAK2/JAK2, and p-STAT3/STAT3, and decreased after low and high dose XSGSJT treatment (p <0.01, as shown in FIG. 3C-FIG. 3F), suggesting that XSGSJT can reverse activation of the IL-6/STAT3 pathway elicited by mastitis models.
(IV) no adverse reaction of rats occurs in the experimental process.
While the foregoing is directed to the preferred embodiment of the present invention, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (4)
1. A traditional Chinese medicine preparation for treating non-lactation mastitis is characterized by being prepared from the following raw materials in parts by weight: 10g of radix bupleuri, 10g of radix scutellariae, 10g of rhizoma cyperi, 30g of dandelion, 10g of fructus forsythiae, 10g of fructus trichosanthis, 10g of fructus gardeniae, 10g of stiff silkworm, 10g of polyporus umbellatus and 10g of poria cocos.
2. A method of preparing a Chinese medicinal formulation for treating non-lactating mastitis as in claim 1, comprising the steps of:
(1) the preparation method comprises the following steps of crushing batryticated silkworm, tuckahoe and grifola according to the formula amount to prepare stiff silkworm powder, tuckahoe powder and grifola powder, adding 65-90% ethanol to extract for two times, 2-3 hours each time, filtering, and collecting a first extracting solution;
(2) slicing fructus forsythiae, extracting volatile oil by steam distillation, and collecting second extractive solution;
(3) mixing the bupleurum, the scutellaria, the rhizoma cyperi, the dandelion, the trichosanthes kirilowii maxim and the gardenia according to the formula amount, adding sufficient distilled water, decocting for 30-60 minutes, and sieving by a 80-mesh sieve to obtain a third extracting solution;
(4) adding the first extracting solution obtained in the step (1) and the second extracting solution obtained in the step (2) into the third extracting solution obtained in the step (3), and performing reduced pressure drying by adopting a cabinet type reduced pressure dryer to obtain dried powder;
(5) further crushing the medicinal powder obtained in the step (4) into fine powder with the granularity of more than 100 meshes by using a traditional Chinese medicine ultrafine pulverizer;
(6) at an ozone concentration of 50g/m3Air flow speed of 40m/s and air source oxygen purity>And (3) performing ozone sterilization on the fine powder obtained in the step (5) at the sterilization temperature of less than 40 ℃ at 85 percent, preserving the medicinal components under the maximum condition, and preparing the Chinese medicinal preparation.
3. The method of claim 2, wherein the fine powder obtained in step (5) is prepared by: 100 percent of the mixture is sieved by a 100-mesh sieve, and 95 percent of the mixture is sieved by a 120-mesh sieve.
4. The method for preparing a Chinese medicinal preparation for treating non-lactation mastitis according to claim 2, wherein the weight of the radix bupleuri, the radix scutellariae, the rhizoma cyperi, the fructus forsythiae, the fructus trichosanthis, the fructus gardeniae, the stiff silkworm, the grifola and the poria cocos in the steps (1), (2) and (3) is the same, and the weight of the dandelion is 3 times of that of any other materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110641774.2A CN113288962B (en) | 2021-06-09 | 2021-06-09 | Traditional Chinese medicine preparation for treating non-lactation mastitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110641774.2A CN113288962B (en) | 2021-06-09 | 2021-06-09 | Traditional Chinese medicine preparation for treating non-lactation mastitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113288962A CN113288962A (en) | 2021-08-24 |
| CN113288962B true CN113288962B (en) | 2022-07-05 |
Family
ID=77327700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110641774.2A Active CN113288962B (en) | 2021-06-09 | 2021-06-09 | Traditional Chinese medicine preparation for treating non-lactation mastitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113288962B (en) |
-
2021
- 2021-06-09 CN CN202110641774.2A patent/CN113288962B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113288962A (en) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN113288962B (en) | Traditional Chinese medicine preparation for treating non-lactation mastitis and preparation method thereof | |
| CN103566300A (en) | Anti-freckle cream and preparation method thereof | |
| CN105477361B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN104825960A (en) | Traditional Chinese medicine for treating pulmonary tuberculosis and preparation method thereof | |
| CN115025150A (en) | Traditional Chinese medicine composition and lotion for treating inflammatory dermatosis | |
| CN100434112C (en) | Pure Chinese medicine for treating hyperplasia of mammary glands and preparing method | |
| CN104189289B (en) | A kind of Chinese medicine for the treatment of acute icterohepatitis and preparation method thereof | |
| CN109172729B (en) | Lung-clearing paste and preparation method thereof | |
| CN104491583A (en) | Traditional Chinese medicine for treating eczema | |
| CN104940617A (en) | Traditional Chinese medicine for treatment of qi-stagnation and blood stasis type chronic pyelonephritis and preparation method | |
| CN105477359B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN105477360B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN104013815A (en) | Traditional Chinese medicine for treating recurrent oral ulcer due to deficiency of yin and excess of heat and preparation method of traditional Chinese medicine | |
| CN116115687B (en) | Traditional Chinese medicine composition for gout and preparation method and application thereof | |
| CN116920066B (en) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof | |
| CN103550480B (en) | Chinese herbal preparation for treating coronary heart disease complicated with hypertension | |
| CN105327149B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN105412609A (en) | Traditional Chinese medicine for treating hepatic stagnation and spleen deficiency type ulcerative colitis and preparation method | |
| Zhang et al. | Research on the rule of homologous TCM applied to epidemic virus infection——Analysis of the results of TCM innovation plan based on bibliometric method | |
| CN105477364B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN117482202A (en) | Traditional Chinese medicine preparation for adjuvant therapy of leukemia and preparation method thereof | |
| CN104983950A (en) | Traditional Chinese medicine for treating spleen and kidney deficiency type chronic pyelonephritis, and preparation method thereof | |
| CN105395889B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |